AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00645866
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00962663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4.
Trial: NCT03062150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03415087
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal injection of fentanyl
Trial: NCT04207684
Drug: Testosterone injection
RxNorm normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
Trial: NCT00305201
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03785340
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
Trial: NCT02684851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00003453
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT05409196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
Trial: NCT04717063
Drug: Peroxyl Oral Product
RxNorm normalized name: Peroxyl Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouth wash
Trial: NCT04717063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo mouth wash
Trial: NCT01303029
Drug: Gemcitabine+erlotinib+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
Trial: NCT02555852
Drug: roxatidine
RxNorm normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: lafutidine
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT01489891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
Trial: NCT00574613
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream 0,3 ml once a day (3 months)
Trial: NCT02832778
Drug: Rifinah or local generics
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
Trial: NCT03364491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Trial: NCT00281944
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00281944
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00615433
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebor Comparator
Trial: NCT03780075
Drug: 1.11GBq of 177Lu-EB-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Trial: NCT03780075
Drug: 2.00 GBq of 177Lu-EB-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Trial: NCT03780075
Drug: 3.70GBq of 177Lu-EB-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Trial: NCT01605916
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Oral bid
Trial: NCT00185367
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
Trial: NCT02374684
Drug: Methosulide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)
Trial: NCT02374684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match with experimental groups
Trial: NCT04493502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04493502
Drug: LY3041658
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02407392
Drug: Acetic Acid
RxNorm normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
Trial: NCT00000473
Drug: fatty acids, omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02108990
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255567
Drug: Paromomycin sulphate
RxNorm normalized name: Paromomycin sulphate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin sulphate
Trial: NCT00255567
Drug: SSG and Paromomycin sulphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSG and Paromomycin Sulphate 17 days
Trial: NCT02507219
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
Trial: NCT01021215
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily given orally for 6 days
Trial: NCT02691533
Drug: ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02691533
Drug: ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02691533
Drug: No Lipid Emulsion/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04039477
Drug: KZR-616
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
Trial: NCT02592408
Drug: 14DPQ on Day 42
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day primaquine starting on day 42
Trial: NCT02433340
Drug: ABT-122
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01920854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01797796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
Trial: NCT00591357
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
Trial: NCT00530179
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 - 21 DAY Cycles of R-CHOP
Trial: NCT03745261
Drug: YCC capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
Trial: NCT03732404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive plain water with the same volume and timing of treatment.
Trial: NCT04360343
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: uncoated tablet
Trial: NCT01052129
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen Sodium Tablets 550 mg
Trial: NCT00335439
Drug: ketorolac tromethamine 0.5% (Acular®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00979810
Drug: 18F-FLT PET Scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
Trial: NCT02218021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02096315
Drug: POL7080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00662233
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00662233
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00701532
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duration 90 days
Trial: NCT00313872
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
Trial: NCT01321151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
Trial: NCT00366262
Drug: PLA-695
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366262
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00366262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02274974
Drug: lidocaine and Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
Trial: NCT00758407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage according to an individual titration schedule
Trial: NCT02266329
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
Trial: NCT02346487
Drug: LPV/RTV pellets and AZT/3TC or ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day
Trial: NCT03751059
Drug: Bromfenac 0.07% Oph Susp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
Trial: NCT02845843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
Trial: NCT01667120
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5mg/kg IV q8h x 72h.
Trial: NCT01667120
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline 1ml/kg
Trial: NCT00383877
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05028907
Drug: 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Trial: NCT05028907
Drug: sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Trial: NCT02465853
Drug: Physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection 0.9% Physiological saline solution\<1.0 ml
Trial: NCT01394991
Drug: Epoetin alfa 450 IU/kg once a week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Trial: NCT04682444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
Trial: NCT01394991
Drug: Epoetin alfa 150 IU/kg 3 times a week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Trial: NCT01466361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01394991
Drug: Epoetin alfa 450 IU/kg once a week (QW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
Trial: NCT01394991
Drug: Epoetin alfa 150 IU/kg 3 times a week (TIW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Trial: NCT03361280
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers are administered as described in arms.
Trial: NCT00417261
Drug: AXT914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02275832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00934375
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02414282
Drug: F 18 T807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Trial: NCT00995969
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g (w/w) placebo cream applied to both target lesions twice daily
Trial: NCT01813929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
Trial: NCT01851993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT04670601
Drug: Flurbiprofen Test 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Trial: NCT04670601
Drug: Flurbiprofen Reference 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Trial: NCT02283788
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02230579
Drug: MMV390048 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Trial: NCT02230579
Drug: MMV390048 120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Trial: NCT02283788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04482686
Drug: Doxycycline Hcl
RxNorm normalized name: doxycycline HCl
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 day treatment
Trial: NCT03592901
Drug: brachial plexus anesthesia
RxNorm normalized name: ACCU-BLOC PLEXUFIX BRACHIAL PLEXUS ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
Trial: NCT02245737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00905372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously (IV) every 4 weeks for 80 weeks
Trial: NCT03540979
Drug: Endometrin 100Mg Vaginal Insert
RxNorm normalized name: Endometrin 100mg Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal tab for lutheal support
Trial: NCT03756987
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be injected in the erector spinae plane.
Trial: NCT04279392
Drug: Zoledronic Acid 5 mg/Bag 100 ml Inj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronic acid infusion
Trial: NCT04279392
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion
Trial: NCT00355459
Drug: Tetracycline: Doxycycline analog
FDA approved: no
EMA approved: no
PMDA approved: no